Predicting heart failure outcome from cardiac and comorbid conditions: the 3C-HF score. International Journal of Cardiology. 2013; 163(2):206-11 305. Seto E, Leonard KJ, Cafazzo JA, Barnsley J, Masino C, Ross HJ. Mobile phone-based telemonitoring for heart failure management: a randomized controlled trial. Journal of Medical Internet Research. 2012; 14(1):e31 306. Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, Liu L et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of 307. Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, O'Meara E et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circulation: Heart Failure. 2014; 7(5):740-51 308. Shah AM, Claggett B, Sweitzer NK, Shah SJ, Deswal A, Anand IS et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation: Heart Failure. 2015; 8(6):1052-8 309. Shah AM, Shah SJ, Anand IS, Sweitzer NK, O'Meara E, Heitner JF et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation: Heart Failure. 2014; 7(1):104-15 Chronic Heart Failure Reference list NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 310. Shah SJ, Heitner JF, Sweitzer NK, Anand IS, Kim HY, Harty B et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation: Heart Failure. 2013; 6(2):184-92 311. Shlipak MG, Smith GL, Rathore SS, Massie BM, Krumholz HM. 